Cancer Abolishes the Tissue Type-specific Differences in the Phenotype of Energetic Metabolism

Overview

Journal Transl Oncol

Specialty Oncology

Date 2009 Aug 25

PMID 19701498

Citations 26

Authors

Paloma Acebo

Daniel Giner

Piedad Calvo

Amaya Blanco-Rivero

Alvaro D Ortega

Pedro L Fernandez

Giovanna Roncador

Edgar Fernandez-Malave

Margarita Chamorro

Jose M Cuezva

Affiliations

Soon will be listed here.

Abstract

Nowadays, cellular bioenergetics has become a central issue of investigation in cancer biology. Recently, the metabolic activity of the cancer cell has been shown to correlate with a proteomic index that informs of the relative mitochondrial activity of the cell. Within this new field of investigation, we report herein the production and characterization of high-affinity monoclonal antibodies against proteins of the "bioenergetic signature" of the cell. The use of recombinant proteins and antibodies against the mitochondrial beta-F1-ATPase and Hsp60 proteins and the enzymes of the glycolytic pathway glyceraldehyde-3-phosphate dehydrogenase and pyruvate kinase M2 in quantitative assays provide, for the first time, the actual amount of these proteins in normal and tumor surgical specimens of breast, lung, and esophagus. The application of this methodology affords a straightforward proteomic signature that quantifies the variable energetic demand of human tissues. Furthermore, the results show an unanticipated finding: tumors from different tissues and/or histological types have the same proteomic signature of energetic metabolism. Therefore, the results indicate that cancer abolishes the tissue-specific differences in the bioenergetic phenotype of mitochondria. Overall, the results support that energetic metabolism represents an additional hallmark of the phenotype of the cancer cell and a promising target for the treatment of diverse neoplasias.

Citing Articles

The role of serum acylcarnitine profiling for the detection of multiple solid tumors in humans.

Wu L, Ye C, Yao Q, Li Q, Zhang C, Li Y Heliyon. 2024; 10(1):e23867.

PMID: 38205321 PMC: 10776988. DOI: 10.1016/j.heliyon.2023.e23867.

IF1 promotes oligomeric assemblies of sluggish ATP synthase and outlines the heterogeneity of the mitochondrial membrane potential.

Romero-Carraminana I, Esparza-Molto P, Dominguez-Zorita S, Nuevo-Tapioles C, Cuezva J Commun Biol. 2023; 6(1):836.

PMID: 37573449 PMC: 10423274. DOI: 10.1038/s42003-023-05214-1.

The Mitochondrial ATP Synthase/IF1 Axis in Cancer Progression: Targets for Therapeutic Intervention.

Dominguez-Zorita S, Cuezva J Cancers (Basel). 2023; 15(15).

PMID: 37568591 PMC: 10417293. DOI: 10.3390/cancers15153775.

IF1 ablation prevents ATP synthase oligomerization, enhances mitochondrial ATP turnover and promotes an adenosine-mediated pro-inflammatory phenotype.

Dominguez-Zorita S, Romero-Carraminana I, Santacatterina F, Esparza-Molto P, Simo C, Del-Arco A Cell Death Dis. 2023; 14(7):413.

PMID: 37433784 PMC: 10336053. DOI: 10.1038/s41419-023-05957-z.

Generation of mitochondrial reactive oxygen species is controlled by ATPase inhibitory factor 1 and regulates cognition.

Esparza-Molto P, Romero-Carraminana I, Nunez de Arenas C, Pereira M, Blanco N, Pardo B PLoS Biol. 2021; 19(5):e3001252.

PMID: 33983919 PMC: 8148373. DOI: 10.1371/journal.pbio.3001252.

References

Matoba S, Kang J, Patino W, Wragg A, Boehm M, Gavrilova O . p53 regulates mitochondrial respiration. Science. 2006; 312(5780):1650-3. DOI: 10.1126/science.1126863. View

Christofk H, Vander Heiden M, Wu N, Asara J, Cantley L . Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature. 2008; 452(7184):181-6. DOI: 10.1038/nature06667. View

Blow N . Antibodies: The generation game. Nature. 2007; 447(7145):741-4. DOI: 10.1038/447741a. View

Wang T, Marquardt C, FOKER J . Aerobic glycolysis during lymphocyte proliferation. Nature. 1976; 261(5562):702-5. DOI: 10.1038/261702a0. View

Ortega A, Sala S, Espinosa E, Gonzalez-Baron M, Cuezva J . HuR and the bioenergetic signature of breast cancer: a low tumor expression of the RNA-binding protein predicts a higher risk of disease recurrence. Carcinogenesis. 2008; 29(11):2053-61. DOI: 10.1093/carcin/bgn185. View

Ramanathan A, Wang C, Schreiber S . Perturbational profiling of a cell-line model of tumorigenesis by using metabolic measurements. Proc Natl Acad Sci U S A. 2005; 102(17):5992-7. PMC: 1087961. DOI: 10.1073/pnas.0502267102. View

Hernlund E, Ihrlund L, Khan O, Ates Y, Linder S, Panaretakis T . Potentiation of chemotherapeutic drugs by energy metabolism inhibitors 2-deoxyglucose and etomoxir. Int J Cancer. 2008; 123(2):476-483. DOI: 10.1002/ijc.23525. View

Cuezva J, Krajewska M, de Heredia M, Krajewski S, Santamaria G, Kim H . The bioenergetic signature of cancer: a marker of tumor progression. Cancer Res. 2002; 62(22):6674-81. View

Ben-Porath I, Thomson M, Carey V, Ge R, Bell G, Regev A . An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet. 2008; 40(5):499-507. PMC: 2912221. DOI: 10.1038/ng.127. View

10.

Hanahan D, Weinberg R . The hallmarks of cancer. Cell. 2000; 100(1):57-70. DOI: 10.1016/s0092-8674(00)81683-9. View

11.

Santamaria G, Martinez-Diez M, Fabregat I, Cuezva J . Efficient execution of cell death in non-glycolytic cells requires the generation of ROS controlled by the activity of mitochondrial H+-ATP synthase. Carcinogenesis. 2005; 27(5):925-35. DOI: 10.1093/carcin/bgi315. View

12.

Lin P, Lin J, Yang S, Wang H, Li A, Chang S . Expression of beta-F1-ATPase and mitochondrial transcription factor A and the change in mitochondrial DNA content in colorectal cancer: clinical data analysis and evidence from an in vitro study. Int J Colorectal Dis. 2008; 23(12):1223-32. DOI: 10.1007/s00384-008-0539-4. View

13.

Schulz T, Thierbach R, Voigt A, Drewes G, Mietzner B, Steinberg P . Induction of oxidative metabolism by mitochondrial frataxin inhibits cancer growth: Otto Warburg revisited. J Biol Chem. 2005; 281(2):977-81. DOI: 10.1074/jbc.M511064200. View

14.

Shin Y, Yoo B, Chang H, Jeon E, Hong S, Jung M . Down-regulation of mitochondrial F1F0-ATP synthase in human colon cancer cells with induced 5-fluorouracil resistance. Cancer Res. 2005; 65(8):3162-70. DOI: 10.1158/0008-5472.CAN-04-3300. View

15.

Haab B . Applications of antibody array platforms. Curr Opin Biotechnol. 2006; 17(4):415-21. DOI: 10.1016/j.copbio.2006.06.013. View

16.

Geschwind J, Ko Y, Torbenson M, Magee C, Pedersen P . Novel therapy for liver cancer: direct intraarterial injection of a potent inhibitor of ATP production. Cancer Res. 2002; 62(14):3909-13. View

17.

Martinez-Diez M, Santamaria G, Ortega A, Cuezva J . Biogenesis and dynamics of mitochondria during the cell cycle: significance of 3'UTRs. PLoS One. 2007; 1:e107. PMC: 1762426. DOI: 10.1371/journal.pone.0000107. View

18.

Bonnet S, Archer S, Allalunis-Turner J, Haromy A, Beaulieu C, Thompson R . A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell. 2007; 11(1):37-51. DOI: 10.1016/j.ccr.2006.10.020. View

19.

Christofk H, Vander Heiden M, Harris M, Ramanathan A, Gerszten R, Wei R . The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature. 2008; 452(7184):230-3. DOI: 10.1038/nature06734. View

20.

Isidoro A, Martinez M, Fernandez P, Ortega A, Santamaria G, Chamorro M . Alteration of the bioenergetic phenotype of mitochondria is a hallmark of breast, gastric, lung and oesophageal cancer. Biochem J. 2003; 378(Pt 1):17-20. PMC: 1223948. DOI: 10.1042/BJ20031541. View